دورية أكاديمية

New-onset Fibromyalgia After Total Knee Replacement in Patients With Osteoarthritis: A Propensity-score-matched Cohort Study in the United States.

التفاصيل البيبلوغرافية
العنوان: New-onset Fibromyalgia After Total Knee Replacement in Patients With Osteoarthritis: A Propensity-score-matched Cohort Study in the United States.
المؤلفون: SHUO-YAN GAU, SHAO-WEI LO, SHIU-JAU CHEN, WEN-CHIEH LIAO, RU-YIN TSAI, YU-JUNG SU, HUI-CHIN CHANG, CHEN-PI LI
المصدر: In Vivo; Jul/Aug2024, Vol. 38 Issue 4, p1957-1964, 8p
مصطلحات موضوعية: FIBROMYALGIA, TOTAL knee replacement, OSTEOARTHRITIS treatment, ELECTRONIC health records
مصطلحات جغرافية: UNITED States
مستخلص: Background/Aim: The risk of new-onset fibromyalgia after total knee replacement (TKR) in osteoarthritis patients is not well-established. This study aimed to assess the risk of developing fibromyalgia post-TKR, considering potential variations across age and sex. Patients and Methods: Utilizing a multicenter retrospective cohort design and data from the TriNetX research network, electronic health records of osteoarthritis patients who underwent TKR and the same number of matched controls were analyzed. Propensity-score matching was performed by matching critical confounders. Hazard ratios were evaluated to assess fibromyalgia risk in the TKR cohort compared to non-TKR controls. Results: The hazard ratio of future fibromyalgia for the TKR cohort was 2.08 (95% confidence interval=1.74-2.49) for 1 year after the index date, 1.81 (95% confidence interval=1.62-2.02) for 3 years, and 1.69 (95% confidence interval=1.54-1.86) for 5 years compared with non-TKR controls. The significant association remained in sensitivity models and stratification analyses in different age and sex subgroups. Conclusion: Clinicians should be vigilant about the potential for fibromyalgia development post-TKR and consider tailored interventions; our findings emphasize the need for further research to elucidate underlying mechanisms and identify modifiable risk factors. [ABSTRACT FROM AUTHOR]
Copyright of In Vivo is the property of International Institute of Anticancer Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:0258851X
DOI:10.21873/invivo.13652